Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.
Benoit BlanchetAlexandre Xu-VuilardAnne JouinotFlorent PuissetDavid CombarelOlivier HuillardFélicien Le LouedecFabienne ThomasMarcus TeixeiraRonan FlippotLoic MoureyLaurence AlbigesThomas PudlarzCharlotte JolyChristophe TournigandJonathan ChauvinAlicja PuszkielEtienne ChatelutXavier DeclevesMichel VidalFrançois GoldwasserStéphane OudardJacques MedioniYann-Alexandre VanoPublished in: British journal of cancer (2024)
Early plasma drug monitoring may be useful to optimise cabozantinib treatment in mRCC patients treated in monotherapy, especially in frail patients starting at a lower than standard dose.
Keyphrases
- metastatic renal cell carcinoma
- end stage renal disease
- newly diagnosed
- ejection fraction
- healthcare
- chronic kidney disease
- palliative care
- combination therapy
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- patient reported outcomes
- chronic pain
- replacement therapy
- smoking cessation
- affordable care act